Internal Medicine, Hematology & Oncology · Chicago, IL
NPI
1588727093
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
5841 S Maryland Ave
Chicago, IL, 60637
Phone (888) 824-0200
Groups this clinician bills Medicare through
Medicare paid, 2024
$39K
453 services
Medicare patients, 2024
114
Average age 70
Drug cost, 2024
$3.6M
291 prescriptions
Company payments, 2025
$11K
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Wendy Stock was code 99233 (hospital e&m - subsequent), 218 times for 42 patients. In total Wendy Stock billed 453 services in 14 codes, and Medicare paid $39K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-10-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 218 | 42 | $96.72 | $21K |
| 99214 Office E&M - Established | Facility | 106 | 51 | $69.28 | $7,343 |
| 99215 Office E&M - Established | Facility | 41 | 21 | $106.68 | $4,374 |
| 99213 Office E&M - Established | Facility | 36 | 22 | $45.27 | $1,630 |
| 99223 Hospital E&M - Initial | Facility | 14 | 12 | $134.54 | $1,884 |
| 99238 Hospital Discharge Management | Facility | 11 | 11 | $66.37 | $730 |
By year: 2022 $27K for 338 services; 2023 $27K for 313 services; 2024 $39K for 453 services.
Medicare prescription drug claims, 2024
In 2024, the drug Wendy Stock prescribed most often to Medicare patients was Iclusig (Ponatinib Hcl), with 55 prescriptions and refills. In total Wendy Stock wrote 291 Medicare prescriptions that cost $3.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Iclusig Ponatinib Hcl | 55 | 55 | Under 11 | $1.1M |
| Venclexta Venetoclax | 48 | 49 | Under 11 | $394K |
| Calquence Acalabrutinib Maleate | 24 | 24 | Under 11 | $370K |
| Acyclovir Generic | 20 | 20 | Under 11 | $107 |
| Tasigna Nilotinib Hcl | 18 | 18 | Under 11 | $181K |
| Imatinib Mesylate Generic | 13 | 21 | Under 11 | $35K |
| Xospata Gilteritinib Fumarate | 11 | 11 | Under 11 | $274K |
Brand drugs: 200 claims; generic drugs: 91 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Wendy Stock $11K ($8,109 in general payments such as food, travel and fees and $2,540 for research) from 9 companies. The largest payer was Amgen Inc. with $4,044.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.